Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
84 Cards in this Set
- Front
- Back
First step in wound healing
|
Clot formation
|
|
First cell type in healing wound
|
Platelet
|
|
Growth factors released by platelets
|
TGF-beta and PDGF
|
|
Phases of wound healing (in order)
|
Inflammatory, proliferative, remodeling
|
|
Most essential cell type for wound healing
|
Macrophage
|
|
Overproduction of this growth factor can result in fibrosis
|
TGF-beta
|
|
Growth factor proven to accelerate wound healing
|
PDGF
|
|
Growth factor involved in tumor metastasis
|
VEGF
|
|
Factors released by endothelium in response to tissue injury
|
PAF and TF
|
|
Primary effector cells in parasitic infections
|
Eosinophils
|
|
Released by mast cells
|
Histamine
|
|
Main source of histamine in the blood
|
Basophils
|
|
Histamine effects
|
Vasodilation, edema, and capillary leak
|
|
Increases cGMP resulting in vascular smooth muscle dilation
|
NO
|
|
Primary cytokines of inflammatory repsonse
|
TNF-alpha and IL-1
|
|
Largest producers of TNF-alpha and IL-1
|
Macrophages
|
|
Cytokine causing cachexia in cancer patients
|
TNF-alpha
|
|
Cytokine predominant in circulatory collapse and MSOF
|
TNF-alpha
|
|
Cytokine most responsible for fevers
|
IL-1
|
|
Cytokine which increases hepatic acute phase proteins
|
IL-6
|
|
Released by lymphocytes in response to viral infections
|
IFN
|
|
Mechanism of action of interferons
|
Inhibit viral replication
|
|
Two major proteins decreased during inflammation
|
Albumin and transferrin
|
|
Cytokine which has been used to treat cancer patients
|
IL-2
|
|
Cytokine which stimulates NK cells to release IFN-gamma and TNF-alpha
|
IL-12
|
|
Cytokine which stimulates IgA production
|
IL-5
|
|
Cytokine which stimulates neutrophil chemotaxis
|
IL-8
|
|
Receptors involved in rolling adhesion of leukocytes
|
Selectins (L - leukocyte; E - endothelial; P - platelets)
|
|
Receptors on leukocytes and platelets involved in tight adhesions and migration
|
Integrins
|
|
Ligands on endothelial cells involved in tight adhesions and migration
|
CAMs
|
|
The classic complement pathway is activated by . . .
|
Antigen-antibody complexes (IgG/IgM)
|
|
The alternative complement pathway is activated by . . .
|
Endotoxin or bacteria
|
|
The convergence point for both complement pathways . . .
|
C3
|
|
Essential element for the complement pathways . . .
|
Mg
|
|
Anaphylatoxins . . .
|
C3a, C4a, C5a
|
|
Membrane attack complex . . .
|
C5b-9b
|
|
Opsonization . . .
|
C3b
|
|
Chemotactic complement factors . . .
|
C3a and C5a
|
|
PGs which cause bronchodilation . . .
|
PGI2 and PGE2
|
|
PG which causes bronchoconstriction . . .
|
PGD2
|
|
Mechanism of anticoagulation by aspirin . . .
|
Decreases TXA2 inhibiting platelet adhesion (irreversible COX inhibition)
|
|
Mechanism by which steroids decrease inflammation . . .
|
Inhibition of phospholipase
|
|
Effect of leukotrienes on bronchioles and blood vessels . . .
|
Bronchoconstriction, vasoconstriction and increased permeability (wheal and flare)
|
|
Timing of peak catecholamines after injury . . .
|
24-48 hours
|
|
Primary cellular mediator of reperfusion injury . . .
|
PMNs
|
|
Chemokine receptor type . . .
|
G-protein-linked
|
|
Rate of epithelialization of a wound . . .
|
1-2 mm/day
|
|
Timing of proliferative phase . . .
|
5 days to 3 weeks
|
|
Rate of peripheral nerve regeneration . . .
|
1 mm/day
|
|
Primary type of collagen in early wound healing . . .
|
Type III
|
|
Primary collagen type in the healed wound . . .
|
Type I
|
|
Role of type IV collagen . . .
|
Basement membrane
|
|
Collagen type in cartilage . . .
|
Type II
|
|
Time at which wound reaches 80% of its final strength . . .
|
6 weeks
|
|
Time at which wound reached 80% of its original strength . . .
|
8 weeks (maximum tensile strength)
|
|
Time at which maximum collagen accumulation occurs . . .
|
2-3 weeks
|
|
Mechanism by which a healing wound regains its strength . . .
|
Collagen crosslinking (remodeling phase)
|
|
Medication which inhibits collagen crosslinking . . .
|
Penicillamine
|
|
Last cell type in a healing wound . . .
|
Fibroblasts
|
|
Two main components of the platelet plug . . .
|
Platelets and fibrin
|
|
Three main components of the provisional matrix (before collagen deposition) . . .
|
1. Platelets
2. Fibrin 3. Fibronectin |
|
Four components of platelet alpha granules . . .
|
1. Platelet factor 4
2. Beta-thrombomodulin 3. PDGF 4. TGF-beta |
|
Three components of platelet dense granules . . .
|
1. Adenosine
2. Serotonin 3. Calcium |
|
Three platelet aggregation factors . . .
|
1. TXA2
2. Thrombin 3. Platelet factor 4 |
|
Prostaglandin which induces vasoconstriction . . .
|
PGF2
|
|
Most important factors in healing by primary and secondary intention respectively . . .
|
Tensile strength and epithelial integrity
|
|
Tensile strength is determined by . . .
|
Collagen deposition and crosslinking
|
|
Epithelial cells migrate from these three locations in a healing wound . . .
|
1. Wound edges
2. Hair follicles 3. Sweat glands |
|
Strength layer of the bowel . . .
|
Submucosa
|
|
Most likely timing of an anastomotic leak . . .
|
Day 3-5
|
|
Cell type involved in wound contraction . . .
|
Myofibroblasts
|
|
Four elements required for hydroxylation and crosslinking of proline . . .
|
1. Vitamin C
2. Alpha-ketoglutarate 3. Fe 4. Oxygen |
|
Two amino acids abundant in collagen . . .
|
Proline and lysine
|
|
Bacterial count which impedes wound healing . . .
|
>100,000/cm2
|
|
Medication administered to counteract steroidal effects on wound healing . . .
|
Vitamin A (25,000 IU daily)
|
|
Defect in osteogenesis imperfecta . . .
|
Type I collagen
|
|
Defect in Marfan's syndrome . . .
|
Fibrillin defect
|
|
Cause and typical location of Charcot's joint . . .
|
Diabetes/ 2nd MTP joint
|
|
Predominant cause and treatment of leg ulcers . . .
|
Venous insufficiency/ Unna boot (zinc oxide)
|
|
Effect of denervation on wound healing . . .
|
None
|
|
Time after which chemotherapy no longer affects wound healing . . .
|
14 days
|
|
Four treatments for keloids . . .
|
1. XRT
2. Steroids 3. Silicone 4. Pressure garments |
|
Typical location of hypertrophic scar tissue . . .
|
Flexor surfaces of upper torso
|
|
Characteristic of collagen in keloids . . .
|
Extends beyond the original scar
|